Usesfulness of transesophageal echocardiographic marker vs CHA2DS2- VASc as predictors of risk increasing of cardioembolic disease in patients with atrial fibillation, Barranquilla,2012
Keywords:
Atrial fibrillatíon, Cardioembolic risk, Transesophageal echocardiographyAbstract
This prospective study was performed to evaluate the usefulness of transesophageal echocardiographic marker vs CHA2DS2-VASc as predictors of risk increasing of cardioembolic disease in patients with atrial fibrillation 35 pa- tients underwent transesophageal echocardiography and clinical stratification. No significant differences between the two methods in predicting risk of stroke events were found. Patients classified as low risk had high-risk echo- cardiographic finding suggesting that it is these that would benefit from the implementation of transesophageal echocardiography for optimum stratification and therapeutic. Transesophageal echocardiography proved useful in detecting predictors of cardioembolic risk in atrial fibrillation appears to be more effective in low-risk patients compared with CHA2DS2-VASc. Due to the small sample size up studies are needed to confirm the accuracy of this finding.
Downloads
References
2.Baena J, Benite W, Bermúdez J, Betancour J, Cabrales M, Cardona H, et al. Guías de diag- nóstico y tratamiento de la fibrilación auricu- lar. Revista Colombiana de Cardiología. 2007; 14:1-141.
3.Lip GY, Nieuwlaat R, Pisters R, Lane DA, Cri- jns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010; 137:263-72.
4.Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost. 2011; 106:528-38.
5.Rodríguez Mañero M, Cordero A, Bertomeu González V, Moreno-Arribas J, Bertomeu- Martínez V, Mazón P, et al. Impacto de los nuevos criterios para el tratamiento anticoa- gulante de la fibrilación auricular. Rev Esp Cardiol. 2011; 64:649-53.
6.Go AS, Hylek EM, Phillips KA, Chang Y, Hen- ault LE, Selby JV, et al. Prevalence of diagno- sed atrial fibrillation in adults: national impli- cations for rhythm management and stroke prevention: the anticoagulation and risk fac- tors in atrial fibrillation (ATRIA) Study. JAMA 2001; 285:2370-5.
7.Camm J, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser S, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. European Heart Journal. 2012; 33:2719-47.
8.Kirchhof P, Bax J, Blomstrom-Lundquist C, Cal-kins H, Camm AJ, Cappato R, et al. Early and comprehensive management of atrial fi- brillation: executive summary of the procee- dings from the 2nd AFNET-EHRA consensus conference ‘Research perspectives in AF’. Eur Heart J. 2009; 30:2969-77c.
9.Zabalgoitia M, Halperin J, Pearce L, Black- shear J, Asinger R, Hart R, et al. Transesopha- geal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998; 31:1622.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
